Insider · CIK 0001559834
Stavros G. Vizirgianakis
Files at APYX (Apyx Medical Corp), XTNT (Xtant Medical Holdings, Inc.). First filing -, latest -.
Stavros G. Vizirgianakis files SEC Form 4 as director at APYX (Apyx Medical Corp), and also at XTNT (Xtant Medical Holdings, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Stavros G. Vizirgianakis has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 4 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 11, 2026 | APYX Apyx Medical Corp | AGrant or award Restricted Stock Units | +450,000 | $0.00 | $0 | 2,196,191 | Jun 15, 2026 |
| Nov 15, 2025 | XTNT Xtant Medical Holdings, Inc. | AGrant or award Common Stock | +553,797 | $0.00 | $0 | 7,515,570 | Nov 18, 2025 |
| May 15, 2025 | APYX Apyx Medical Corp | AGrant or award Stock Option (Option to Buy)derivative | +128,000 | $0.00 | $0 | 128,000 | May 19, 2025 |
| Jan 15, 2025 | APYX Apyx Medical Corp | AGrant or award Stock Option (Option to Buy)derivative | +50,000 | $0.00 | $0 | 50,000 | Jan 17, 2025 |
Questions about Stavros G. Vizirgianakis
Answered from the filings on this page, as of the latest one.
Is Stavros G. Vizirgianakis buying or selling?
Stavros G. Vizirgianakis has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Stavros G. Vizirgianakis's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Stavros G. Vizirgianakis has 0.
Where does Stavros G. Vizirgianakis file Form 4?
Stavros G. Vizirgianakis has filed Form 4 at APYX (Apyx Medical Corp); XTNT (Xtant Medical Holdings, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.